Open Access

Erratum to: Patient costs of breast cancer endocrine therapy agents under Medicare Part D vs with generic formulations

  • Ann Butler Nattinger1, 4Email author,
  • Liliana E Pezzin1, 4,
  • Emily L McGinley4,
  • John A Charlson2, 4,
  • Tina W F Yen3, 4 and
  • Joan M Neuner1, 4
SpringerPlus20154:531

https://doi.org/10.1186/s40064-015-1233-y

Published: 21 September 2015

The original article was published in SpringerPlus 2015 4:54

Erratum to: SpringerPlus (2015) 4:54 DOI 10.1186/s40064-015-0827-8

It has come to our attention that during production of the original article, some of the column headings were missing from Tables 1 and 2. The corrected Tables 1 and 2 can be found below. The publisher apologises for any inconvenience caused.
Table 1

Trajectory of costs under Medicare Part D for breast cancer adjuvant endocrine agents prior to generic availability

Medication

Monthly cost after deductible

Monthly cost in gap

Monthly cost in catastrophic

Median of state mean costs

Median of state mean costs

Median of state mean costs

$, (Range of mean costs)

$, (Range of mean costs)

$, (Range of mean costs)

2007

2010

Change (%)

2007

2010

Change (%)

2007

2010

Change (%)

Arimidex

39.64 (38.37–48.19)

62.83 (60.00–74.75)

+58

258.64 (247.44–263.47)

392.84 (375.66–418.58)

+52

13.18 (12.68–13.32)

19.65 (19.03–20.93)

+49

Aromasin

42.57 (40.72–50.94)

86.50 (81.51–101.08)

+103

267.56 (255.21–273.62)

353.98 (351.86–377.07)

+32

13.66 (13.07–13.79)

17.70 (17.59–18.85)

+30

Femara

41.92 (39.38–51.11)

89.03 (80.95–102.77)

+112

277.65 (249.14–282.54)

433.42 (430.46–461.42)

+56

14.16 (12.96–14.34)

21.67 (21.55–23.07)

+53

Tamoxifen

6.19 (5.95–9.22)

5.98 (5.66–6.75)

−3

21.32 (20.36–25.42)

15.52 (15.03–18.90)

−27

2.26 (2.20–2.70)

2.60 (2.58–2.75)

+15

Table 2

Trajectory of costs under Medicare Part D for breast cancer adjuvant endocrine agents before and after availability of generic alternatives

Medication

Monthly cost after deductible

Monthly cost in gap

Monthly cost in catastrophic

Median of state mean costs

Median of state mean costs

Median of state mean costs

$, (Range of mean costs)

$, (Range of mean costs)

$, (Range of mean costs)

2007

2011a

Change (%)

2007

2011a

Change (%)

2007

2011a

Change (%)

Arimidex/Anastrozole

39.64 (38.37–48.19)

9.57 (8.00–11.95)

−76

258.64 (247.44–263.47)

38.94 (31.80–78.46)

−85

13.18 (12.68–13.32)

3.72 (3.39–6.19)

−72

Aromasin/Exemestane

42.57 (40.72–50.94)

49.50 (42.34–118.68)

+16

267.56 (255.21–273.62)

244.51 (228.61–270.95)

−9

13.66 (13.07–13.79)

14.41 (13.51–71.41)

+6

Femara/Letrozole

41.92 (39.38–51.11)

69.31 (59.69–85.17)

+65

277.65 (249.14–282.54)

225.13 (209.10–252.23)

−19

14.16 (12.96–14.34)

38.53 (33.70–57.15)

+172

Tamoxifen

6.19 (5.95–9.22)

5.54 (5.12–6.89)

−11

21.32 (20.36–25.42)

13.17 (12.44–21.11)

−38

2.26 (2.20–2.70)

2.73 (2.50–3.47)

+21

aFirst year generic formulation was available to Medicare Part D beneficiaries; generic cost provided

Notes

Authors’ Affiliations

(1)
Division of General Internal Medicine, Medical College of Wisconsin
(2)
Division of Hematology-Oncology, Medical College of Wisconsin
(3)
Division of Surgical Oncology, Medical College of Wisconsin
(4)
Center for Patient Care and Outcomes Research, Medical College of Wisconsin

Copyright

© Nattinger et al. 2015